Quantcast

Latest Boehringer Ingelheim Pharmaceuticals Inc. Stories

2014-09-18 08:28:26

- Boehringer Ingelheim obtains exclusive global rights for development and commercialization of CureVac's investigational therapeutic cancer vaccine CV9202 INGELHEIM and TUBINGEN, Germany, and RIDGEFIELD, Conn., Sept. 18, 2014 /PRNewswire/ -- Boehringer Ingelheim and CureVac, leader in mRNA (messenger ribonucleic acid)-based drug development, today jointly announce an exclusive global license and development collaboration. The new collaboration focuses on CureVac's CV9202, a novel...

2014-09-10 12:24:27

RIDGEFIELD, Conn., Sept. 10, 2014 /PRNewswire/ -- In support of Pulmonary Fibrosis Awareness Month, Boehringer Ingelheim Pharmaceuticals, Inc., announces the airing of Every Breath Counts: Idiopathic Pulmonary Fibrosis -- a documentary supported by the company and created in collaboration with the Pulmonary Fibrosis Foundation and the Coalition for Pulmonary Fibrosis in an effort to increase awareness and understanding of idiopathic pulmonary fibrosis (IPF) among the general public....

2014-09-09 08:32:06

For U.S. Media Only RIDGEFIELD, Conn., Sept. 9, 2014 /PRNewswire/ -- A pre-specified, pooled subgroup sensitivity analysis from the two identically designed Phase III INPULSIS(TM) trials, presented today at the European Respiratory Society International Congress (ERS) evaluated the impact of the investigational drug nintedanib on reducing the decline in lung function, as measured by annual rate of decline in forced vital capacity (FVC), in patients with idiopathic pulmonary fibrosis (IPF)...

2014-09-08 12:30:18

Additionally, data from the WISDOM trial on stepwise withdrawal of ICS in COPD was also presented at ERS and simultaneously published in the New England Journal of Medicine RIDGEFIELD, Conn., Sept. 8, 2014 /PRNewswire/ -- Boehringer Ingelheim today presented the first data from the pivotal Phase III TONADO(TM) 1&2 studies (NCT01431274/NCT01431287) for the fixed-dose combination (FDC) of tiotropium plus olodaterol delivered via the Respimat(®) inhaler in patients with moderate to...

2014-09-08 12:29:32

For U.S. Media Only RIDGEFIELD, Conn., Sept. 8, 2014 /PRNewswire/ -- Boehringer Ingelheim today presented new data from the company's Phase III trial program (UniTinA-asthma(®)) evaluating tiotropium in asthma, including the first study assessing the efficacy and safety of tiotropium in adolescent patients with symptomatic asthma. These data were unveiled during an oral session at the European Respiratory Society (ERS) International Congress 2014 in Munich, Germany. Tiotropium is...

2014-09-02 08:30:31

Patients at higher risk of kidney problems due to existing diabetes were also evaluated for the effects of warfarin on kidney function RIDGEFIELD, Conn., Sept. 2, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a new post-hoc sub-analysis of the pivotal phase III RE-LY® trial assessing renal function change in patients with non-valvular atrial fibrillation (NVAF) treated with Pradaxa® (dabigatran etexilate mesylate) compared to warfarin. The...

2014-08-26 08:31:41

New JARDIANCE Simple Savings program currently offered in doctors' offices and online RIDGEFIELD, Conn. and INDIANAPOLIS, Aug. 26, 2014 /PRNewswire/ -- Jardiance(®) (empagliflozin) tablets are now available by prescription in pharmacies across the United States, including Walgreens, Rite Aid, Kroger and many other leading chain and independent retailers, according to Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY). The U.S. Food and Drug Administration...

2014-08-25 08:27:31

Hot Line session presentations to feature renal function data from pivotal RE-LY® trial and global GLORIA(TM)-AF registry updates RIDGEFIELD, Conn., Aug. 25, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that data from nine company-sponsored Pradaxa® (dabigatran etexilate mesylate) studies will be presented at the European Society of Cardiology (ESC) Congress 2014, August 30 to September 3 in Barcelona, Spain. The abstracts will feature data about the use...

2014-08-19 12:28:32

For U.S. Media Only RIDGEFIELD, Conn., Aug. 19, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for the fixed-dose combination (FDC) of tiotropium and olodaterol delivered via the Respimat(®) inhaler for the proposed indication of long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including...

2014-08-18 20:21:55

INDIANAPOLIS and RIDGEFIELD, Conn., Aug. 18, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today granted tentative approval for Basaglar(TM) (insulin glargine injection), which is indicated to improve glycemic control in adults with type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with type 1 diabetes. Basaglar is not recommended for the treatment of diabetic ketoacidosis. Basaglar is Eli Lilly and Company (NYSE: LLY) and...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related